Cannabinoids

Willow Biosciences and Cellular Goods Announce Multiyear Supply Agreement for Cannabigerol (CBG)

Retrieved on: 
Thursday, June 10, 2021

VANCOUVER, BC, June 10, 2021 /PRNewswire/ - Willow Biosciences Inc.("Willow" or the "Company") (TSX:WLLW) (OTCQX: CANSF), a biotechnology company producing ultra-pure, sustainably made compounds, and Cellular Goods PLC ("Cellular Goods") (LSE: CBX), a U.K. based provider of premium consumer products based on biosynthetically made cannabinoids, are announcing today that the two companies have signed a multi-year supply agreement, whereby Willow will supply Cellular Goods with its proprietary, ultra-pure, biosynthetically produced, cannabigerol ("Willow CBG") to be used in Cellular Goods' premium cannabinoid-based skin care products to be launched in autumn of 2021.

Key Points: 
  • VANCOUVER, BC, June 10, 2021 /PRNewswire/ - Willow Biosciences Inc.("Willow" or the "Company") (TSX:WLLW) (OTCQX: CANSF), a biotechnology company producing ultra-pure, sustainably made compounds, and Cellular Goods PLC ("Cellular Goods") (LSE: CBX), a U.K. based provider of premium consumer products based on biosynthetically made cannabinoids, are announcing today that the two companies have signed a multi-year supply agreement, whereby Willow will supply Cellular Goods with its proprietary, ultra-pure, biosynthetically produced, cannabigerol ("Willow CBG") to be used in Cellular Goods' premium cannabinoid-based skin care products to be launched in autumn of 2021.
  • The Company's first shipment of Willow CBG to Cellular Goods is expected to arrive in July of this year.
  • Alexis Abraham, Cellular Goods Chief Executive Officer, said: "Successful products start with the best ingredients and being able to source consistent, highly-pure cannabinoids via cellular agriculture from a trusted provider like Willow is essential to our business.
  • Trevor Peters, Willow's President & Chief Executive Officer, said: "We are very excited to announce our first commercial supply agreement for CBG.

Rapid Therapeutic Finalizes Lab Work on Pharmaceutical Formulas

Retrieved on: 
Thursday, June 10, 2021

RTSL has developed three (3) proprietary pharmaceutical formulas, two (2) for cannabidiol (CBD) and one (1) for cannabigerol (CBG), to initially be used in Metered Dose Inhalers (MDI).

Key Points: 
  • RTSL has developed three (3) proprietary pharmaceutical formulas, two (2) for cannabidiol (CBD) and one (1) for cannabigerol (CBG), to initially be used in Metered Dose Inhalers (MDI).
  • RTSLs CEO, Donal R. Schmidt, Jr. stated, We initially set out to find an ultra-pure, unadulterated pharmaceutical grade CBD isolate to use in our MDI.
  • We also learned CBD isolate is not chemically compatible with metered dose inhalers without significant modifications in the manufacturing process.
  • In short, we were unsatisfied with any product we could source in the hemp space to meet our needs.

Innocan Pharma Among Leading CBD Pharma Companies to Participate at Lytham Partners Summer 2021 Investor Conference

Retrieved on: 
Wednesday, June 9, 2021

Iris Bincovich, CEO will participate on the "CBD Treatments" discussion panel on Monday June 14 at 11:00AM ET.

Key Points: 
  • Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 9, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that it will participate at the Lytham Partners Summer 2021 Investor Conference on June 14 through June 16, 2021.
  • Management will also be participating in virtual one-on-one meetings throughout the event, which run from June 14 through June 16, 2021.
  • The Company, through its wholly owned Israeli subsidiary, Innocan Pharma Ltd. ("Innocan Israel"), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol ("CBD").
  • The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference

Retrieved on: 
Wednesday, June 9, 2021

VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (CBN), today announced that Eric.

Key Points: 
  • VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (CBN), today announced that Eric.
  • A. Adams, President and CEO of InMed, will present at 2021 BIO Digital, the premier biotech conference, which is being held virtually this year from June 10-11 and 14-18, 2021.
  • The presentation will be available on demand to registered attendees during the conference, starting June 10th at 9am ET.
  • About InMed: InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (CBN), in diseases with high unmet medical need.

Deep Six CBD Debuts Delta 8 THC Baked Goods, Chocolate Bars Online, Delivery Anywhere in the USA Including NJ, MD, FL, GA, Texas.

Retrieved on: 
Friday, June 4, 2021

"We've heard the stories from our parents and grandparents," explained Nicholas Kruczaj, cannabis entrepreneur and president of Deep Six CBD.

Key Points: 
  • "We've heard the stories from our parents and grandparents," explained Nicholas Kruczaj, cannabis entrepreneur and president of Deep Six CBD.
  • Delta 8 THC, or THC 8, is an important alternative to medical marijuana for customers who won't, or can't, visit dispensaries.
  • Customers order Delta 8 THC baked goods to their favorite summer spots in Virginia Beach, Orlando & Atlanta ahead of time.
  • THC 8 milk chocolate, dark chocolate, and cookies & cream bars give a much-needed sugar rush.

Chairman of New You, Inc. CBD Acquisition Subsidiary ST Brands to Speak on Panel Entitled "The Companies Driving International Market Growth" at the Benzinga Cannabis Capital Conference, Thursday, June 3

Retrieved on: 
Wednesday, June 2, 2021

New You, Inc. (OTCQB: NWYU) wholly-owned subsidiary ST Brands Corp is a capital and growth platform for high potential consumer cannabidiol (CBD) companies that create, develop, market, and sell unique and proprietary products to various segments of the global consumer market.

Key Points: 
  • New You, Inc. (OTCQB: NWYU) wholly-owned subsidiary ST Brands Corp is a capital and growth platform for high potential consumer cannabidiol (CBD) companies that create, develop, market, and sell unique and proprietary products to various segments of the global consumer market.
  • ST Brands applies financial, operational, branding resource infrastructure to deliver turnkey business services and achieve economies of scale in capital, sourcing, production, packaging, and sales.
  • ST Brands acquires scalable cannabis companies with the potential to become sector leaders in the legal cannabis market.
  • The conference will feature an interactive forum of live presentations from top CEOs, investors, and leaders in the cannabis space.

Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th

Retrieved on: 
Wednesday, June 2, 2021

LA JOLLA, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.

Key Points: 
  • LA JOLLA, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.
  • Gregory D. Gorgas, Artelos President and CEO, is scheduled to host a virtual presentation to investors during the event as follows:
    For more information on the LD Micro Invitational XI, or to register for the event, please visit https://ldmicrojune2021.mysequire.com .
  • Artelo Biosciences, Inc.is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting endogenous signaling pathways including the endocannabinoid system.
  • Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation.

Global Cannabidiol (CBD) Market Size Expected to Reach $55 Billion In 2028

Retrieved on: 
Wednesday, June 2, 2021

Due to the increasing adoption of CBD-based products to treat ailments, the global cannabidiol market is anticipated to grow at a lucrative rate over the forecast period.

Key Points: 
  • Due to the increasing adoption of CBD-based products to treat ailments, the global cannabidiol market is anticipated to grow at a lucrative rate over the forecast period.
  • They also stated that the market is projected to grow from USD 3,675.1 million in 2021 to USD 55,791.3 million in 2028 at a CAGR of 47.49% between 2021 and 2028.
  • Fortune Business Insights added: "Cannabidiol is extracted from cannabis or hemp, but more specifically from hemp due to its naturally high CBD content.
  • The market is evolving faster due to its increasing utilization in the cosmetics , food, and pharmaceuticals industry.

Global Cannabidiol (CBD) Market Size Expected to Reach $55 Billion In 2028

Retrieved on: 
Wednesday, June 2, 2021

Due to the increasing adoption of CBD-based products to treat ailments, the global cannabidiol market is anticipated to grow at a lucrative rate over the forecast period.

Key Points: 
  • Due to the increasing adoption of CBD-based products to treat ailments, the global cannabidiol market is anticipated to grow at a lucrative rate over the forecast period.
  • They also stated that the market is projected to grow from USD 3,675.1 million in 2021 to USD 55,791.3 million in 2028 at a CAGR of 47.49% between 2021 and 2028.
  • Fortune Business Insights added: "Cannabidiol is extracted from cannabis or hemp, but more specifically from hemp due to its naturally high CBD content.
  • The market is evolving faster due to its increasing utilization in the cosmetics , food, and pharmaceuticals industry.

Cannabinol (CAS 521-35-7) Global Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 1, 2021

The "Cannabinol (CAS 521-35-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cannabinol (CAS 521-35-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Cannabinol.
  • The fifth chapter deals with Cannabinol market trends and forecast, distinguish Cannabinol manufacturers and suppliers.
  • The Cannabinol global market report key points: